SAN DIEGO, November 30, 2021 – ProSciento, Inc., a specialty clinical research organization (CRO) focused exclusively on metabolic diseases, is pleased to announce that it has become the first California-wide sponsor of JDRF’s Northern California and Southern California One Walks. Each year, JDRF One Walks across California bring together more than 10,000 walkers to raise awareness, support research, and fund programs to make a difference in the lives of individuals affected by type 1 diabetes (T1D).
ProSciento is a longtime supporter of JDRF, a global organization funding T1D research. Since 2007, ProSciento has participated in the JDRF San Diego Gala, TypeOneNation Summit, and One Walk events, contributing more than $100,000 from fundraising and sponsorship to support T1D research.
“ProSciento is delighted to announce our California-wide partnership with JDRF and this expanded opportunity to share our core values of making a positive difference in the lives of patients with metabolic diseases through meaningful clinical research and partnerships with patient advocacy groups. We want to thank JDRF for the tremendously impactful work that they are doing on behalf of the T1D and overall diabetes community, locally, regionally and ultimately, across the country and the globe,” commented Dr. Marcus Hompesch, ProSciento’s Chairman and Chief Executive Officer.
“One Walk activities are a key strategy for raising funds and awareness about our continuing work to find a cure for type 1 diabetes. We are honored to have ProSciento join us as a sponsor in this life-changing work. Their commitment allows us to reach more people living with T1D, and their loved ones, in our efforts to expand knowledge of much needed new treatments and cutting-edge technologies under development,” commented Michelle Popoff, JDRF Southern California Chapter Executive Director.
Founded in 1970, JDRF is the world’s largest nonprofit funder of T1D research. Its exclusive focus is on finding a cure, and in pursuit of that goal, the organization is making daily advancements that improve the lives of those living with the disease. JDRF’s research has two core objectives: Cures by restoring the body’s ability to make insulin and stopping T1D before it occurs or providing insulin independence through replacement with insulin producing cells; and Improving Lives by keeping people with T1D as healthy as possible until cures are found by advancing new T1D resources, technologies, and therapies. JDRF has a five-year plan for making Cures for T1D closer to reality.
About ProSciento, Inc.
ProSciento is a metabolism-focused, full scope clinical research organization (CRO), with a mission to advance the global development of therapeutics for type 1 and type 2 diabetes, nonalcoholic steatohepatitis (NASH), and obesity. ProSciento works with biopharma companies worldwide to support their outsourced clinical research needs with comprehensive and customized services for multinational, early development clinical trial programs. Founded in 2003, ProSciento has conducted more than 350 clinical studies for diabetes, NASH, and obesity, and has contributed to the development of numerous approved metabolic drugs and devices on the global marketplace. For more information, please visit www.prosciento.com.
For business development inquiries, please contact:
For media inquiries, please contact:
Senior Director, Corporate Communications, ProSciento, Inc.